This week at ADA 2026
Amycretin just became zenagamtide in New Orleans — and the Phase 2b data dropped on Sunday
The American Diabetes Association's 2026 Scientific Sessions opened Thursday in New Orleans, and Novo Nordisk arrived with a rename and a dataset. Amycretin — the GLP-1 and amylin receptor dual agonist that has been circulating in metabolic medicine circles since its [Phase 1/2 obesity data was published in The Lancet](https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html) — officially became zenagamtide this week as Novo Nordisk revealed its international nonproprietary name. Phase 2b results in type 2 diabetes were presented Sunday at the conference, per the [official ADA 2026 press release](https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html). The Phase 3 REDEFINE program for obesity is currently enrolling. If any of this sounds familiar, it is because amycretin has been the most-watched name in Novo Nordisk's pipeline since one number — 24.3% — escaped the footnotes of a small Phase 1 trial and started doing outsized work in the public conversation.
The actual biology
One molecule targeting two appetite pathways at once — and neither of them is GIP
GLP-1 receptor agonism is what semaglutide does, and it is what makes the entire current class of obesity medicines commercially transformative. It suppresses appetite through gut-brain axis signaling, slows gastric emptying, and drives glucose-dependent insulin secretion. Amycretin does all of that — but it is engineered as a single molecular entity that simultaneously activates the amylin receptor as well. Amylin is a peptide co-secreted alongside insulin from pancreatic beta cells. It acts through distinct brainstem pathways, particularly the area postrema and nucleus tractus solitarius, to produce post-meal satiety signals that do not overlap mechanistically with GLP-1's action. The pharmacological hypothesis is that layering amylin-pathway satiety onto GLP-1-mediated appetite suppression produces a more complete inhibitory signal than either receptor can generate alone — and that the combination may perform better than single-pathway drugs while keeping a manageable side-effect profile. This design distinguishes amycretin from tirzepatide, which pairs GLP-1 with GIP rather than amylin, and from cagrisema, which combines two separate molecules rather than engineering dual receptor activity into one compound. [The PubMed literature on amycretin](https://pubmed.ncbi.nlm.nih.gov/?term=amycretin) documents the mechanistic framework that preceded both the obesity and diabetes clinical programs.
What the internet says
A Phase 1 number has been doing Phase 3-level work in the weight-loss discourse since 2024
The metabolic medicine community and the broader wellness-podcast audience latched onto amycretin after a specific data point escaped the fine print of a Phase 1b/2a trial and became a comparison tool. In forums, optimization circles, and longevity-adjacent channels through late 2025 and early 2026, the presentation went like this: tirzepatide achieves roughly 20 to 22 percent weight reduction in Phase 3, amycretin already hit 24.3 in Phase 1/2, therefore amycretin is the clear next step up. The logic sounds clean. It collapses a real methodological problem. Phase 1/2 results come from small, carefully selected populations, on dose-finding schedules, without the statistical architecture of pivotal Phase 3 trials. They are designed to establish safety and preliminary efficacy signals, not to produce the powered endpoint data that regulatory decisions depend on. The 24.3% figure came from 125 participants over 36 weeks. Tirzepatide's comparable figures come from thousands of participants across multiple Phase 3 programs. Those two data points are not directly comparable. The oral version's 13.1% at 12 weeks has attracted similar framing against oral semaglutide's more modest weight-loss profile — fair in direction but needing the same Phase 3 caveat the subcutaneous data needs. None of this makes the Phase 1/2 numbers unimpressive. It makes Phase 3 necessary before those numbers can carry the weight the online discussion is placing on them.
What the data actually shows
Lancet-published Phase 1/2 data is real — and Phase 3 REDEFINE is now enrolling
The Phase 1b/2a trial results that put amycretin on the map were published in The Lancet and evaluated 125 adults with obesity or overweight over 36 weeks. The highest subcutaneous dose produced a mean 24.3% weight reduction versus 1.1% with placebo, per the [Novo Nordisk Phase 3 advancement announcement](https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html). A separate Phase 1 oral study produced 13.1% weight loss over 12 weeks at 100 mg per day versus 1.2% for placebo. Both trials reported primarily mild to moderate gastrointestinal adverse events consistent with the GLP-1 drug class. Phase 2b data presented this week at ADA 2026 extended the dataset to type 2 diabetes, where earlier readouts reported up to 14.5% weight loss alongside meaningful HbA1c reductions in 448 participants. [ClinicalTrials.gov for amycretin](https://clinicaltrials.gov/search?term=amycretin) shows the registered trial footprint, including the REDEFINE Phase 3 obesity program now enrolling and the Phase 3 diabetes program planned for the second half of 2026. The data is genuine, Lancet-published, and conference-presented at ADA this week. What is not yet present is a pivotal Phase 3 result in thousands of participants with pre-specified endpoints that would support an approval application.
Early human — PeptideFactCheck stance
Real published data with a Phase 3 now enrolling — and no approval until that trial reads out
Amycretin carries the Early human evidence tier on PeptideFactCheck, and that label is precisely right for where this drug sits in June 2026. The data is real: peer-reviewed, Lancet-published, presented at ADA this week, backed by a Phase 3 program that is now actually enrolling rather than merely announced. Early human means interesting enough to watch — and for amycretin, the signal is strong enough that Novo Nordisk moved directly to Phase 3 development for both the subcutaneous and oral formulations simultaneously rather than running additional Phase 2 work first. What the tier also marks is the distance between a promising Phase 1/2 result and a regulatory decision. The 24.3% figure is the most-discussed Phase 1/2 weight-loss number in metabolic medicine right now, and the amylin dual-agonism story is pharmacologically coherent enough to make the REDEFINE readout a genuine watch event. None of that changes the fact that no approved label exists for any indication. The [FDA guidance on unapproved GLP-1 and GLP-1-adjacent products](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) distinguishes investigational drugs in active formal development — which amycretin is — from the unapproved gray-market products that borrow the language of the class without the clinical infrastructure behind it. Amycretin, now zenagamtide, has the infrastructure. The Phase 3 is when the evidence tier might move.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.